Because periarticular bone changes predate deleterious cartilage changes [ 20, 40, 41, 57], it has been speculated that drugs targeting bone may have a disease-modifying effect in OA.
It has been speculated that the use of nonsteroidal anti-inflammatory drugs (NSAIDs) during and after surgery could not only modify the tumor microenvironment in which micrometastasis are present but also reduce migration and invasion of circulating malignant cells; therefore, the administration of these drugs in the perioperative period might have a significant impact on cancer recurrence 11– 11.
It has been speculated that Beijing strains are growing in prevalence in some regions of the world and that they are prone to drug resistance [ 31, 32].
The reason for these high rates of amoxicillin resistance remains unclear, however, since no pharmaco-epidemiological data regarding amoxicillin use in Brazil exists, it may be speculated that this drug is used in a disproportionate manner.
It might therefore be speculated that compulsive drug seeking arises from the development of qualitatively aberrant, rigid, maladaptive habits in vulnerable individuals that are characterized by premorbid alterations in corticostriatal-dependent inhibitory control processes.
Moreover, it can be speculated that among cardiovascular drugs, the ones with the ancillary property of improving endothelial function are possibly preferable in the treatment of risk factors.
Furthermore it could be speculated that rather than a drug that targets both SUR1 and SUR2 isoforms, such as glibenclamide, a SUR1-specific drug, such as gliclazide, might influence neurological symptoms more effectively as only SUR1 isoforms are present in neuronal KATP channels.
Although this clinical scenario could be affected by numerous parameters, it might be speculated that G allele could result in enhancement of the drug metabolism.
Therefore, it was speculated that the ATPase activity of OtrC-ORF1 is stimulated by doxorubicin and other drugs.
As Watson Pharmaceuticals coughs up $1.9 billion to acquire rival Andrx, one analyst is speculating that other makers of geneic drugs will face increased pressure to bulk up as well.
